Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

Cancer

Volumn 116, Issue 11, 2010, Pages 2665-2672

  Kantarjian, Hagop ^a   Le Coutre, Phillipp ^b   Cortes, Jorge ^a   Pinilla Ibarz, Javier ^c   Nagler, Arnon ^d   Hochhaus, Andreas ^e   Kimura, Shinya ^f   Ottmann, Oliver ^g  

^a UNIVERSITY OF TEXAS   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f SAGA UNIVERSITY   (Japan)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

Chronic myeloid; INNO 406; Leukemia; Philadelphia positive; Resistance

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; DASATINIB; GLUTAMIC ACID; GLYCINE; HISTIDINE; IMATINIB; ISOLEUCINE; LYSINE; NILOTINIB; PROLINE; THREONINE; TYROSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE MARROW DISEASE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CODON; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; LIVER DYSFUNCTION; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; PAIN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 77952840150     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25079     Document Type: Article

References (24)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
4. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321-1331. (Pubitemid 39136739)
5. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004;9:259-270. (Pubitemid 38756875)
6. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109:2171-2181. (Pubitemid 46801546)
7. Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007;2007:371-375.
8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
9. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw. 2005;3:757-768.
10. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145:913-923. (Pubitemid 351639967)
11. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005;106:3948-3954.
12. Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl dual tyrosine kinase inhibitor. Anal Chem Insights. 2007;2:93-106.
13. Ernst T, Hoffmann J, Erben P, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2008;93:1389-1393.
14. Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008;93:186-192. (Pubitemid 351397706)
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880. (Pubitemid 32743979)
16. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther. 2008;8:1387-1398.
17. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French Intergroup of CML (Fi/-LMC Group). Leukemia. 2006;20:1061-1066.
18. Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007;109:306-314. (Pubitemid 46053071)
19. Deguchi Y, Kimura S, Ashihara E, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res. 2008;32:980-983.
20. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib- resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541. (Pubitemid 43882349)
21. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
22. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309. (Pubitemid 46425867)
23. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546. (Pubitemid 350159618)
24. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep. 1966;50:219-244.